Polyrizon Appoints Dr. Michal Meir to Spearhead Regulatory and Clinical Affairs
In a strategic move to enhance its clinical trial capabilities, Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company at the forefront of developing innovative intranasal hydrogels, has announced the appointment of Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs. This decision comes as the company prepares for the clinical trial of PL-14, anticipated to start in 2025.
Dr. Meir's Extensive Experience
Dr. Meir brings to Polyrizon over ten years of experience in the medical device and pharmaceutical sectors. Her career includes significant roles at Medtech SME Ltd., Keystone Heart, and Alma Lasers, where she demonstrated exceptional skill in navigating complex regulatory environments and leading clinical initiatives that have propelled innovation and facilitated market access.
A Strategic Addition to the Team
"We are confident that Michal's profound expertise in regulatory and clinical affairs will be a tremendous asset as we continue to pursue our mission of delivering state-of-the-art solutions," stated Tomer Izraeli, CEO of Polyrizon. He emphasized that Dr. Meir's strategic insights and leadership are expected to enhance the company's capabilities and play a crucial role in the successful development and approval of its products.
Commitment to Excellence
Dr. Meir's appointment underscores Polyrizon's dedication to upholding the highest standards of regulatory compliance and clinical excellence. Her notable accomplishments include managing global regulatory submissions, devising clinical strategies for new medical devices, and authoring essential regulatory and clinical documents.
This strategic appointment is a clear indication of Polyrizon's commitment to advancing its clinical trial efforts and achieving its goal of bringing innovative treatments to market.
